Fluoxetine versus trimipramine in the treatment of depression in geriatric patients

Pharmacopsychiatry

Volumn 38, Issue 1, 2005, Pages 13-16

  Wehmeier, P M ^a   Kluge, M ^a   Maras, A ^b   Riemann, D ^c   Berger, M ^c   Kohnen, R ^d   Dittmann, R W ^a,e   Gattaz, Wagner F ^f  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d IMEREM   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ADJECTIVE MOOD SCALE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HAMILTON SCALE; HEART ARRHYTHMIA; HUMAN; MALE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROTOXICITY; PATIENTS GLOBAL IMPRESSION SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZATION; RATING SCALE; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; VISUAL DISORDER;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TRIMIPRAMINE;

EID: 14044257777     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837765     Document Type: Article

References (17)

1. Adli M, Rush AJ, Möller HJ, Bauer M. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 2003; 36 (Suppl. 3): S222-229
2. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36
3. Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, Falkai P, Haarmann C, Berger M, Gastpar M. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double-blind comparison with the phenothiazine perazine. Pharmacopsychiatry 2003; 36: 61-69
4. Frieboes RM, Sonntag A, Yassourides A, Eap CB, Baumann P, Steiger A. Clinical outcome after trimipramine in patients with delusional depression: A pilot study. Pharmacopsychiatry 2003; 36: 12-17
5. Koetsier GC, Volkers AC, Tulen JH, Passchier J, van den Broek WW, Bruijn JA. CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. J Psychiatr Res 2002; 36: 391-397
6. Kurzthaler I, Hotter A, Miller C, Kemmler G, Halder W, Rhomberg HP, Fleischhacker W. Risk profile of SSRIs in elderly depressive patients with co-morbid physical illness. Pharmacopsychiatry 2001; 34: 114-118
7. Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitryptiline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8: 147-153
8. Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: Selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149-157
9. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-analysis. Brit Med J 2003; 326: 1014-1019
10. Nurnberg HG, Thomson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatr 1999; 60: 574-579
11. Ohishi M, Kamijima K. A comparison of characteristics of depressed patients and efficacy of sertraline and amitriptyline between Japan and the West. J Affect Disord 2002; 70: 165-173
12. Riedel-Heller SG, Matschinger H, Schork A, Angermeyer MC. The utilization of antidepressants in community-dwelling and institutionalized elderly: Results from a representative survey in Germany. Pharmacopsychiatry 2001; 34: 6-12
13. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Rüther E, Wiegand MH, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Meyer G, Berger M. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 65-174
14. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Huyser J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004; 37: 32-36
15. Volkers AC, Tulen JH, van den Broek WW, Bruyn JA, Passchier J, Pepplinkhuizen L. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder. Pharmacopsychiatry 2004; 37: 18-25
16. von Zerssen D. Self-rating scales for evaluation of patients' subjective state in cross-sectional and longitudinal studies of psychopathology. Arch Psychiatr Nervenkr 1973; 217: 299-314
17. Wolf R, Dykierek P, Gattaz WF, Maras A, Kohnen R, Dittmann RW, Geuppert M, Riemann D, Berger M. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001; 34: 60-65